GlassScriptPhysician profile
Vanessa Nwokoye
NPI 1205530045
$1,630.98
in general payments reported to CMS, 2019-2025
16 companies · $584 in 2025
The $584 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $172 · 2024: $875 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,630.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $490.70 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $319.01 | 2023-2025 | Otezla, Evenity, Repatha |
| Novo Nordisk INC | $225.79 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $127.52 | 2023-2025 | Resonate El Icd Vr, Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $120.85 | 2025 | |
| Lilly USA, LLC | $50.72 | 2023-2024 | Mounjaro |
| Azurity Pharmaceuticals, INC. | $44.80 | 2023 | Edarbi |
| Abbvie INC. | $36.54 | 2025 | |
| Exact Sciences Corporation | $34.91 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $34.27 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $29.23 | 2024 | |
| Dexcom, INC. | $24.84 | 2025 | Dexcom G6 Transmitter |
| Cvrx, INC. | $24.31 | 2024 | Barostim Neo System |
| Renalytix Ai, INC. | $22.93 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Glaxosmithkline, LLC. | $22.44 | 2025 | Trelegy Ellipta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $22.12 | 2023 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Nwokoye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.